Emerging Treatment Options for Myelofibrosis: Focus on Anemia.

Publication Year: 2023

DOI:
10.2147/TCRM.S386802

PMCID:
PMC10315142

PMID:
37404252

Journal Information

Full Title: Ther Clin Risk Manag

Abbreviation: Ther Clin Risk Manag

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Health Care Sciences & Services

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Disclosure Dr Douglas Tremblay reports grants, personal fees from CTI Biopharma, grants from Astellas Pharma, grants from Gilead, personal fees from Novartis, personal fees from AbbVie, personal fees from Sierra Oncology, personal fees from GSK, personal fees from Cogent Biosciences, outside the submitted work. The authors report no other conflicts of interest in this work."

Evidence found in paper:

"Disclosure: Dr Douglas Tremblay reports grants, personal fees from CTI Biopharma, grants from Astellas Pharma, grants from Gilead, personal fees from Novartis, personal fees from AbbVie, personal fees from Sierra Oncology, personal fees from GSK, personal fees from Cogent Biosciences, outside the submitted work. The authors report no other conflicts of interest in this work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025